3-D Mammography Significantly Reduces Breast Biopsy Rates

Released: March 19, 2019

OAK BROOK, Ill. — The use of digital breast tomosynthesis (DBT), also known as 3-D mammography, may significantly reduce the number of women who undergo breast biopsy for a non-cancerous lesion following an abnormal mammogram, according to a new study published in the journal Radiology.

Unlike standard or full-field digital mammography (FFDM), which captures two x-ray images of the breast from top-to-bottom and from side-to-side, DBT captures multiple images from different angles that are synthesized into 3-D images by a computer.

“The thin slice images of the breast taken with DBT reduce the effect of tissue overlap, which often leads to cancers being missed or to women who don’t have breast cancer being recalled for diagnostic imaging,” said lead researcher Nisha Sharma, M.B.Ch.B., director of breast screening and clinical lead for breast imaging at Leeds Teaching Hospital NHS Trust, Seacroft Hospital, in Leeds, England. “In our study, we wanted to determine the impact of DBT on the biopsy rate among women recalled for an abnormal screening mammogram.”

The single-institution prospective study included 30,933 women who had a screening FFDM or screening breast MRI through the U.K.’s National Health Service Breast Screening Programme (NHSBSP) at Seacroft Hospital between 2015 and 2016. Within six weeks of their breast screening, the women also underwent DBT.

Of the study group, 1,470 women were recalled for further imaging (4.8 percent recall rate) to assess an abnormality. A final recall group of 827 women after exclusions (mean age 56.7 years) required 571 biopsies, yielding a biopsy rate of 69 percent. Biopsy detected 142 cancers. In 429 of the biopsies performed, the suspicious lesion detected on screening mammography was not cancerous, for a benign biopsy rate of 75 percent.

The researchers read the DBT images blinded to the original FFDM screening results to determine whether 3-D images would have influenced the biopsy recommendation. The inclusion of DBT imaging would have reduced the number of biopsies performed on recalled women from 571 to 298—while still detecting the 142 cancers—for a biopsy rate of 36 percent, and a benign biopsy rate of 52 percent.

“DBT allows for improved reader accuracy and confidence in determining if a mammographic abnormality is concerning or not, leading to a reduction in the number of biopsies performed,” Dr. Sharma said. “Our study validates that DBT can help in the diagnostic workup of mammographic abnormalities and reduce harm to women through fewer false positive biopsies without any reduction in the cancer detection rate.”

At A Glance

- Digital breast tomosynthesis (DBT) may significantly reduce breast biopsy rates for non-cancerous lesions.
- Researchers analyzed data from 30,933 women from the United Kingdom’s National Health Service Breast Screening Program.
- DBT reduced the biopsy rate from 69 percent to 36 percent without any reduction in the cancer detection rate.

“All The Potential Impact of Digital Breast Tomosynthesis on the Benign Biopsy Rate in Women Recalled within the UK Breast Screening Programme.”

Collaborating with Dr. Sharma were Michelle McMahon, M.B., B.Ch., B.A.O., Isobel Haigh, M.B.Ch.B., Yan Chen Ph.D., and Barbara J.G. Dall, M.B.Ch.B.

Radiology is edited by David A. Bluemke, M.D., Ph.D., University of Wisconsin School of Medicine and Public Health, Madison, Wis., and owned and published by the Radiological Society of North America, Inc. (https://pubs.rsna.org/journal/radiology)

RSNA is an association of over 53,400 radiologists, radiation oncologists, medical physicists and related scientists, promoting excellence in patient care and health care delivery through education, research and technologic innovation. The Society is based in Oak Brook, Ill. (RSNA.org)

For patient-friendly information on breast imaging visit RadiologyInfo.org.
Figure 1. (a) Flowchart shows the National Health Service Breast Screening Programme pathway used in the United Kingdom. Women with abnormal full-field digital mammography (FFDM) results are recalled for screening assessment, which involves triple assessment (clinical examination, diagnostic mammography, and targeted US of the abnormality). (b) Study flowchart shows the hypothetical effect of triple assessment with digital breast tomosynthesis (DBT) and demonstrates the potential number of biopsies that would have been performed with the addition of DBT in triple assessment.

High-res (TIF) version
(Right-click and Save As)

Figure 2. Images in a 63-year-old asymptomatic woman who was recalled because a new 8-mm mass was detected in the left breast at screening mammography. (a) Left mediolateral oblique and (b) left mediolateral oblique spot compression mammograms show an 8-mm partly ill-defined mass (arrow) in the upper breast. (c) Left mediolateral oblique digital breast tomosynthesis (DBT) image shows an 8-mm well-defined mass (arrow) in the upper breast. The mass was interpreted as benign at DBT and was coded R2 benign; however, it was indeterminate at full-field digital mammography. Targeted US of the breast revealed normal findings, and stereotactic biopsy yielded a diagnosis of micropapillary ductal carcinoma in situ (DCIS). Wide local surgical excision revealed a 5-mm high-grade DCIS.

High-res (TIF) version
(Right-click and Save As)
Figure 3. Images in a 46-year-old asymptomatic woman who was recalled for asymmetry in the right breast that was assessed as benign on further diagnostic mammograms and in whom targeted US findings were normal. Full-field digital mammography findings were false negative, and biopsy revealed intermediate ductal carcinoma in situ. (a) Right mediolateral oblique (MLO) and (b) lateral views. (c) Right MLO digital breast tomosynthesis (DBT) image shows an indeterminate spiculated density that was coded R3 indeterminate. Stereotactic-guided DBT biopsy was performed and revealed a papilloma with atypia. The patient underwent surgical diagnostic biopsy, which showed a 4-mm intermediate-grade ductal carcinoma in situ.